A Green Sign – Lifestyle
Author:
Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
April 20, 2026
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
April 16, 2026
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
April 16, 2026
Trevi Therapeutics to Participate in Upcoming Events
April 1, 2026
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
March 17, 2026
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
March 10, 2026
RideNow Group, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
March 10, 2026
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
March 9, 2026
Trevi Therapeutics to Participate in Upcoming March Conferences
March 5, 2026